Photo detail

Phillip Britanabe, senior research associate at Halozyme, tests PEGPH20 in the company’s lab.

Stories this photo appears in:

Platform Delivers For Halozyme

BIOTECH: Co. Finds Right Balance for Work On Drug, Delivery System

Halozyme Therapeutics seeks big returns on two fronts. Royalties in one could hit nearly $1 billion by 2027. The other holds even bigger potential.

Tease photo